INDP Indaptus Therapeutics Inc
Company Analysis
Latest News
🔴 Indaptus Therapeutics is trading 10.86% down today after continued profit-taking
Indaptus Therapeutics is trading 10.86% down at $1.15 after continued profit-taking following its 46.81% surge on August 20 and 6.52% decline on August 21. -...
🔴 Indaptus Therapeutics is trading 6.96% down in pre-market amid biotech-sector weakness and reduced momentum
Indaptus Therapeutics is trading 6.96% down at $1.20 after continued profit-taking following its 46.81% surge on August 20 and 6.52% decline on August 21. -...
🔴 Indaptus Therapeutics is trading 11.59% down today on profit-taking and broader biotech-sector weakness
Indaptus Therapeutics is trading 11.59% down at $1.22, apparently due to profit-taking and broader biotech-sector weakness rather than a new company-specific...
🔴 Indaptus Therapeutics is trading 7.97% down today after profit-taking following the prior session’s sharp advance
Indaptus Therapeutics is trading 7.97% down at $1.27, primarily amid biotech-sector weakness and profit-taking after the prior session’s sharp advance. -...
🔴 Indaptus Therapeutics is trading 6.52% down in pre-market after a 46.81% prior-session surge
Indaptus Therapeutics is trading $1.29 (-6.52%) after a sharp 46.81% advance to $1.38 on August 20. - No major August 21 company announcement or overnight...
🟢 Indaptus Therapeutics is trading 26.39% up today with no clear catalyst identified
Indaptus Therapeutics is trading 26.39% up at $1.19, with no clear company-specific catalyst identified for August 20, 2026. - Latest notable disclosures were...
🟢 Indaptus Therapeutics is trading 6% up today with no clear catalyst identified
Indaptus Therapeutics is trading 5.97% up at $1.00, with no fresh company-specific announcement identified on August 20, 2026. - Latest notable disclosures...
🟢 Indaptus Therapeutics is trading 11.1% up today as Moderna’s positive cancer-vaccine results lift biotech
Indaptus Therapeutics is trading 11.1% up at $1.04, outperforming the broader market as biotechnology sentiment improves following Moderna’s positive...
Indaptus Therapeutics Files 59M Share Resale Amid Going-Concern Warning
Indaptus Therapeutics filed for a secondary offering of up to 58,895,000 common shares by selling stockholders. The company will not sell any shares or receive...
🔴 Indaptus Therapeutics is trading 5.66% down today as risk-off sentiment weighs on markets
Indaptus Therapeutics is trading 5.66% down now at $0.94, with the decline appearing aligned with broader risk-off sentiment. - Shares fell 6.54% to $1.00 on...
🟢 Indaptus Therapeutics is trading 5.33% up in pre-market despite no clearly reported company-specific announcement
Indaptus Therapeutics is trading 5.33% up at $1.05 despite no clearly reported company-specific announcement on August 18, 2026. - The latest identifiable...
🟢 Indaptus Therapeutics is trading 5% up in after-hours trading
Indaptus Therapeutics is trading 5% up at $1.05 in after-hours trading after closing at $1.00 on August 17, 2026; no major company-specific announcement tied...
🔴 Indaptus Therapeutics is trading 8.4% down today after Decoy20 trial discontinuation
Indaptus Therapeutics is trading at $0.98 (-8.40%) on August 17, 2026, following its August 13 second-quarter report and corporate update, alongside the...
🟢 Indaptus Therapeutics is trading 14% up today after sharply narrower losses and strategic shift
Indaptus Therapeutics is trading 14.02% up at $1.22 after its August 13, 2026 second-quarter report highlighted sharply narrower losses and a strategic shift...
🟢 Indaptus Therapeutics is trading 7% up today
Indaptus Therapeutics is trading 7.01% up now at $1.15, extending its recent rebound after closing at $1.07 on August 14, 2026. - No new company-specific...
Indaptus Shares Jump 8.5% on Narrower Losses, but With No Drug in the Clinic, What Exactly Are Investors Buying?
Shares of Indaptus Therapeutics shifted sharply higher on Aug. 14, rising 8.5% to $1.15, after the micro-cap biotech reported second-quarter results that beat...
🟢 Indaptus Therapeutics is trading 8.5% up today after Q2 results reportedly beat estimates
Indaptus Therapeutics is trading 8.5% up now at $1.15 after its August 13, 2026, second-quarter results reportedly beat estimates, with a narrowed $1.8 million...
🟢 Indaptus Therapeutics is trading 5.66% up in pre-market after net loss narrows to $1.8 million
Indaptus Therapeutics is trading 5.66% up in pre-market at $1.12 after August 13, 2026, second-quarter results showed net loss narrowing to approximately $1.8...
🟢 Indaptus Therapeutics is trading 5.65% up in after-hours trading after reporting a narrower second-quarter loss
Indaptus Therapeutics is trading 5.65% up at $1.12 in after-hours trading after its August 13, 2026, second-quarter earnings release and narrower loss. - Net...
🟢 Indaptus Therapeutics is trading 5% up today after narrower second-quarter loss
Indaptus Therapeutics is trading 5.32% up now at $1.08 after reporting second-quarter 2026 results on August 13, 2026. - Net loss narrowed to $1.8 million...